Rutaecarpine attenuates osteoclastogenesis by impairing macrophage colony stimulating factor and receptor activator of nuclear factor κ‐B ligand‐stimulated signalling pathways. (25th July 2018)

• Record Type: Journal Article
• Authors: Fukuma, Yutaka; Sakai, Eiko; Komaki, Shunsuke; Nishishita, Kazuhisa; Okamoto, Kuniaki; Tsukuba, Takayuki
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 45:Number 8(2018)
• Page Start: 863
• Page End: 865
• Publication Date: 2018-07-25
• Subjects: bone marrow‐derived macrophages -- osteoclast differentiation -- rutaecarpine; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.12941
• Languages: English
• ISSNs: 0305-1870

Abstract

Summary: Rutaecarpine is a major alkaloid isolated from Evodia rutaecarpa . Here, we investigated the effects of rutaecarpine on osteoclast differentiation induced by macrophage colony stimulating factor (M‐CSF) and receptor activator of nuclear factor κ‐B ligand (RANKL) in bone marrow‐derived macrophages (BMMs). Treatment with rutaecarpine significantly inhibited osteoclastogenesis and prevented bone resorption of BMM‐derived osteoclasts. Mechanistically, rutaecarpine decreased the protein level of nuclear factor of activated T cells cytoplasmic‐1 (NFATc1) and the phosphorylation of other signalling pathways during the osteoclast differentiation. Thus, rutaecarpine may be useful as a therapeutic agent for the treatment of bone diseases.